Treatment of advanced head and neck cancer: What lessons have we learned?

Journal of Clinical Oncology

Volumn 24, Issue 7, 2006, Pages 1023-1025

  Conley, Barbara A ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; PACLITAXEL; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; BACTEREMIA; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG RESPONSE; EDITORIAL; FIBROSIS; HEAD AND NECK CANCER; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND DISEASE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CHEMISTRY; EPIDEMIOLOGY; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; METHODOLOGY; NOTE; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; RISK FACTOR; SURVIVAL; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH DESIGN; RISK FACTORS; SELECTION BIAS; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 33644987230     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.0682     Document Type: Editorial

References (19)

1. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data - MACH-NC Collaborative Group: Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955, 2000
2. Department of Veterans Affairs Cooperative Laryngeal Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685-1690, 1991
3. Lefebvre JL, Chevalier D, Luboinski B, et al: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial - EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:855-856, 1996
4. Ries LAG, Eisner MP, Kosary CL, et al (eds): SEER Cancer Statistics Review, 1975-2002, National Cancer Institute, Bethesda, MD. http://seer.cancer. gov/csr/1975_2002/
5. Taylor JC, Terrell JE, Ronis DL, et al: Disability in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 130:764-769, 2004
6. Adelstein DJ, Saxton JP, Rybicki LA, et al: Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: Mature results from a single institution. J Clin Oncol 24:1064-1071, 2006
7. Brockstein B, Haraf DJ, Rademaker AW, et al: Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337 patient, multi-institutional experience. Ann Oncol 15:1179-1186, 2004
8. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636-8645, 2005.
9. Adelstein DJ, Li Y, Adams GL, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
10. Pivot X, Magne N, Guardiola E, et al: Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol 41:320-327, 2005
11. Hitt R, Ciruelos E, Amador ML, et al: Prognostic value of the epidermal growth factor receptor (EGRFsic) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction therapy. Eur J Cancer 41:453-460, 2005
12. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356, 2002
13. Ang KK, Andratschke NH, Milas L, et al: Epidermal growth factor receptor and response of head and neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 58:959-965, 2004
14. Burtness B, Goldwater MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/ recurrent head and neck cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol 23:8646-8654, 2005
15. Baselga J, Trigo JM, Bourhis J, et al: Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23:5568-5577, 2005
16. Herbst RS, Arquette M, Shin DM, et al: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23:5578-5587, 2005
17. Bonner JA, Giralt J, Harari P, et al: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of the head and neck: A phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 22:488, 2004 (suppl, abstr 5507)
18. Pfister DG, Su YB, Kraus DH, et al: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24:1072-1078, 2006
19. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000